

Discovery of Small-Molecule Immunotherapeutics Dual-Targeting TAM and Treg in the Tumor Microenvironment

Chung-Ang University/College of Pharmacy



ONCOLOGY	Lead
Product Type	Small molecule
Indication	Melanoma and lung cancer
Target	PI3K δ & CSF1R
MoA(Mechanism of Action)	Immune activation by reduction of Treg and TAM in tumor microenvironment
Competitiveness	<ul style="list-style-type: none">- High potency for CSF1R and PI3Kδ- High selectivity for PI3Kδ among PI3K subtypes (α, β, γ)- Good kinase inhibition profile
Development Stage	Lead
Route of Administration	Oral